3Jarai R,Dangas G,Huber K,et al.B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial [J]. Circ Cardiovasc Interv. 2012(5):813-820.
6Jarai R, Huber K, Bogaerts K. et al. Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatmen! and Thrombolysis in Myocardial lnfaretion (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treat- ment Strategy with Percutaneous Coronary Intervention (ASSENT IV- PC1) tria[J].Am Heart J. 2010(159):131-140.
7Lassus JP, Nieminen MS, Peuhkurinen K, et 'al. Markers of renal func- tion and acute kidney injury in acute heart failure: definitions and im- pact on out-comes of the cardiorenal syndrome[J].Eur Heart J. 2010(31): 2791-2798.
8Zhang J,Fu X,Jia X. et al. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention [J]. Acta Radiol.2010 Jul;51 (6):641-648.
9RIHAL C S, TEXTOR S C, GRILL D E, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention [ J ]. Circulation, 2002, 105 (19) : 2259- 2264.
10MEHRAN R, AYMONG E D, NIKOLSKY E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation[J]. J Am Coil Cardiol, 2004, 44(7): 1393-1399.
